Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy

Akira Goto, Yasutaka Sukawa, Hisayoshi Igarashi, Kei Onodera, Yuka Aoki, Kazuya Suzuki, Kazuhiko Yonezawa, Atsushi Yawata, Toshihisa Kobayashi, Hiroyuki Kaneto, Haruo Shimizu, Hideki Wakasugi, Yasutaka Matsunaga, Miki Itoh, Hiroyuki Okuda, Yoshiaki Arimura, Yasuhisa Shinomura

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: S-1, an oral fluoropyrimidine, is one of the standard chemotherapeutic agents for the treatment of metastatic gastric cancer (MGC). However, the most effective second-line regimen after failure of treatment with first-line agents such as S-1 is yet to be determined. The aim of this study was to investigate the various second-line chemotherapy regimens in MGC patients. Methods: We retrospectively studied patients with MGC who received second-line treatment after failure of the first-line S-1 or S-1/cisplatin treatment. The overall survival times with each second-line regimen were determined using the Kaplan-Meier method, and the effect on overall survival was analyzed using Cox regression analysis. Results: The median survival time for all patients was 14.2 months (95% confidence interval (CI): 12.88-15.43 months) with a 1-year survival rate of 60.4%. Kaplan-Meier analysis revealed that the second-line regimens containing irinotecan significantly improved the median survival time as compared to regimens without irinotecan (median survival time: 16.5 and 13.8 months, respectively). Cox regression analysis showed that irinotecan-containing regimens were associated with improved overall survival (hazard ratio: 0.165; 95% CI: 0.041-0.665). Conclusion: The use of irinotecan-containing regimens as second-line chemotherapy after failure of first-line S-1 therapy may be beneficial for MGC patients.

Original languageEnglish
Pages (from-to)1461-1466
Number of pages6
JournalJapanese Journal of Cancer and Chemotherapy
Volume38
Issue number9
Publication statusPublished - 2011 Sep 1

Keywords

  • Gastric cancer
  • Irinotecan
  • S-1
  • Second-line chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy'. Together they form a unique fingerprint.

  • Cite this

    Goto, A., Sukawa, Y., Igarashi, H., Onodera, K., Aoki, Y., Suzuki, K., Yonezawa, K., Yawata, A., Kobayashi, T., Kaneto, H., Shimizu, H., Wakasugi, H., Matsunaga, Y., Itoh, M., Okuda, H., Arimura, Y., & Shinomura, Y. (2011). Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy. Japanese Journal of Cancer and Chemotherapy, 38(9), 1461-1466.